UK Pharmaceutical Drug Market

Tirzepatide, sold as Mounjaro, became the costliest medicine dispensed in English community pharmacies in the year to March 2026, at GBP 574 million, up from GBP 120 million a year earlier, while 1.30 billion items cost GBP 11.6 billion in total, up 4%, the NHS Business Services Authority (NHSBSA) Prescription Cost Analysis of 4 June 2026 shows. Six months earlier, on 10 December 2025, the government set the 2026 rebate on newer branded medicines at 14.5%, down from 22.9% in 2025, its payment notice for the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) states. The UK pharmaceutical drug market covers the finished prescription and over-the-counter medicines sold to the National Health Service (NHS), community pharmacies, hospitals, online pharmacies and private patients in England, Scotland, Wales and Northern Ireland, valued at manufacturer invoice prices, across branded biologics, branded small molecules, generics, biosimilars and over-the-counter (OTC) medicines. Douglas Insights sizes it at USD 38.1 billion in 2025, about GBP 29.0 billion, from 47.8 billion defined daily doses (DDDs) at an average USD 0.798 a dose, and at USD 59.8 billion in 2035, a 4.60% compound annual growth rate (CAGR). The study is the United Kingdom row of our Europe Pharmaceutical Drug Market model, which itself sits inside our worldwide Pharmaceutical Drug Market report and beside our Germany Pharmaceutical Drug Market study, within our pharmaceuticals coverage, and every figure follows the Douglas Insights research methodology.

Which product type earns the most pharmaceutical drug value: branded small molecules, biologics or biosimilars?

Branded small molecules earn the most UK pharmaceutical drug value, 32.5% of 2025 or USD 12.4 billion, Douglas Insights estimates. Biosimilars are the fastest-growing segment, at 10.8% a year from USD 2.67 billion to USD 7.44 billion by 2035.

Branded small molecules, USD 12.4 billion, lead because the UK still spends heavily on patented tablets for heart failure, diabetes, anticoagulation and cancer, but they grow only 3.30% a year as exclusivity ends. The NHSBSA data show how fast that happens: dapagliflozin 10 mg (Forxiga) produced the largest fall in community cost in 2025/26, down GBP 249.4 million, after generic entry in 2025, and AstraZeneca’s results of 30 October 2026 flag “generic entry in the UK in Q3 2025” for the same drug. Branded biologics, USD 11.8 billion, grow faster, 5.50% a year, to become the largest UK pharmaceutical drug segment by 2035 at USD 20.2 billion, carried by cancer antibodies, antibody-drug conjugates and immunology injectables used mostly in hospitals.

Generics, USD 6.86 billion, are 86.1% of community items in England yet only 55.7% of community cost, the NHSBSA 2025/26 summary narrative shows, so they grow 3.60% a year, mostly on volume. Over-the-counter medicines, USD 4.38 billion, grow 3.20% as pharmacies take more minor ailments under the Pharmacy First service. Biosimilars, USD 2.67 billion, grow fastest because NHS England’s national tenders switch patients to copies of ustekinumab and aflibercept within months of patent expiry, a Douglas Insights estimate. Product-type values for 2035 sum to USD 60.6 billion, 1.30% above the USD 59.8 billion headline.

Which therapy areas and channels lead pharmaceutical drug spending?

Oncology leads UK pharmaceutical drug spending by therapy area, about 19.5% of 2025 value or USD 7.43 billion, Douglas Insights estimates, and diabetes and obesity follow at 14.0%. By channel, retail pharmacy takes 49.0% and hospitals 44.5%.

Oncology, about USD 7.43 billion, leads because the UK uses many high-cost immunotherapies and targeted drugs through the Cancer Drugs Fund. Diabetes and obesity, about USD 5.34 billion, is the fastest-growing therapy area at about 8.1% a year: the endocrine chapter of the British National Formulary took 21% of English community cost in 2025/26, up from 19% a year earlier, and semaglutide added GBP 137.8 million, the NHSBSA narrative shows. Immunology takes about 12.0%, USD 4.57 billion; central nervous system medicines 11.0%, USD 4.19 billion; respiratory 9.0%, USD 3.43 billion, led by inhalers such as beclometasone with formoterol at GBP 284.8 million; cardiovascular 8.2%, USD 3.13 billion; vaccines and anti-infectives 7.8%, USD 2.97 billion; and all other areas 18.5%, all Douglas Insights estimates.

By channel, retail pharmacy, USD 18.7 billion, grows 3.80% a year; hospital pharmacy, USD 17.0 billion, grows 4.90% as specialty injectables move into outpatient clinics; online pharmacy, USD 2.48 billion, grows fastest at 9.60% on private weight-loss prescriptions and NHS app repeat orders. Hospitals already issue about half of NHS medicine value in England: GBP 11.1 billion of an estimated GBP 21.6 billion in 2024/25, before rebates, against GBP 10.3 billion prescribed in primary care, the NHSBSA Prescribing Costs in Hospitals and the Community release of 20 November 2025 shows. Channel values for 2035 sum to USD 60.7 billion, 1.54% above the headline.

What drives pharmaceutical drug spending per daily dose up 3.87% a year to 2035: launches, obesity drugs or the pricing reset?

UK pharmaceutical drug spending per daily dose rises 3.87% a year, from USD 0.798 in 2025 to about USD 1.17 in 2035, because specialty launches, obesity drugs, Britain’s pricing reset and ageing add 4.60 gross points before restraints of 0.73 points.

Daily doses grow only 0.70% a year, from 47.8 billion to about 51.3 billion, as the population ages and long-term conditions spread; English community items rose 3% to 1.30 billion in 2025/26, per the NHSBSA release, but much of that rise is cheap generic tablets. Four drivers make up the gross price-and-mix leg.

Specialty launches in cancer and immunology: 1.90 points

New specialty medicines add 1.90 points, the largest driver. The Medicines and Healthcare products Regulatory Agency (MHRA) approved 921 medicinal products in 2025/26, “including 39 new medicines”, its annual report release of 16 July 2026 states, and each new cancer or immunology drug replaces cheaper care at a higher price per dose. AstraZeneca’s European revenue rose 10% at constant exchange rates (CER) to USD 10.5 billion in the first nine months of 2026, and GSK’s Specialty Medicines sales rose 15% to GBP 3.88 billion in the third quarter, its results of 28 October 2026 show. Douglas Insights estimates that a new specialty medicine adds about USD 60 million of UK sales by its third year.

Glucagon-like peptide-1 (GLP-1) and obesity medicines: 1.25 points

Obesity and diabetes add 1.25 points. Tirzepatide items in English community pharmacies rose from 1.1 million to 3.1 million in 2025/26 and the average cost per item from GBP 108 to GBP 187, the NHSBSA narrative shows; one drug now takes about 4.9% of community cost. The private market adds more: Eli Lilly raised the UK list price of the highest Mounjaro dose from GBP 122 to GBP 330 a month from September 2025, a rise of up to 170% that did not apply to NHS supply, Reuters reported on 14 August 2025.

Britain’s pricing reset: 0.85 points

The pricing reset adds 0.85 points. The 2026 VPAG rate of 14.5% on newer medicines replaces 22.9% and “is capped at a maximum of 15%” from 2026, the government notice says. The National Institute for Health and Care Excellence (NICE) raised its threshold to GBP 25,000 to GBP 35,000 per quality-adjusted life year (QALY), from GBP 20,000 to GBP 30,000, for medicines considered from April 2026, which should add “three to five” approvals a year, the Pharmaceutical Journal reported on 2 December 2025.

Ageing and long-term conditions: 0.60 points

Ageing adds the last 0.60 points, because older patients take more medicines and more of them are injectables. Summed, 1.90 + 1.25 + 0.85 + 0.60 = 4.60 points; after 0.73 points of restraints the price leg is 3.87%, and (1.0070 x 1.0387) minus 1 gives the 4.60% revenue rate, a Douglas Insights estimate.

What holds back pharmaceutical drug prices: patent expiries, NHS budgets or lost investment?

Three restraints remove 0.73 points a year from UK pharmaceutical drug price growth: loss of exclusivity takes 0.45 points, NHS budget control 0.18 points and launch delays linked to investment and U.S. pricing 0.10 points, Douglas Insights estimates.

Loss of exclusivity is the largest brake. When generics arrive, English Drug Tariff prices fall quickly: the Forxiga fall of GBP 249.4 million in a single year, per the NHSBSA narrative, equals 2.1% of English community cost. Apixaban 5 mg tablets gave the largest fall a year earlier, down GBP 131.4 million in 2024/25. Douglas Insights expects USD 4.1 billion of UK branded sales to face generic or biosimilar entry between 2026 and 2030, which removes 0.45 points a year.

NHS budget control removes 0.18 points. Older branded medicines still pay VPAG rates of 10% to 35%, and member companies pay an extra 1% investment contribution, so the total newer-medicines rate in 2026 is 15.5% of revenue, the Association of the British Pharmaceutical Industry (ABPI) said on 10 December 2025. Launch delays remove 0.10 points: MSD, as Merck & Co. is known outside North America, scrapped a planned GBP 1 billion London research centre on 11 September 2025, citing “the overall undervaluation of innovative medicines and vaccines” by UK governments, The National reported, and U.S. most-favoured-nation pricing gives companies reason to delay launches in low-price markets.

Which UK nation buys the most pharmaceutical drugs: England, Scotland, Wales or Northern Ireland?

England buys the most UK pharmaceutical drugs, USD 31.9 billion or 83.6% of 2025 value, and grows fastest at 4.62% a year to USD 50.1 billion by 2035, Douglas Insights estimates. Scotland follows with USD 3.39 billion.

England leads on scale and on growth. Its NHS spent an estimated GBP 21.6 billion on medicines in 2024/25 before GBP 660 million of central rebates, up 5.3% from GBP 20.5 billion, the NHSBSA release shows, and NICE decisions apply there first. England’s 4.62% rate is also helped by the aligned MHRA and NICE pathway that launched on 1 April 2026 and brings new medicines to patients “up to six months” sooner, the government said on 17 March 2026.

Scotland, USD 3.39 billion, spends about 10% more per head than England, a Douglas Insights estimate, because of free prescriptions and higher chronic disease rates, but grows 4.45% under the Scottish Medicines Consortium’s separate appraisals. Wales, USD 1.79 billion, also has free prescriptions and grows 4.40%, the slowest of the four because its population is static. Northern Ireland, USD 1.07 billion, grows 4.55% as it follows NICE guidance for most new medicines. Nation values sum to USD 39.9 billion in 2026, 0.01% below the headline, and USD 59.7 billion in 2035, 0.07% below it.

Who sells the most pharmaceutical drugs, and how concentrated is the field?

Eli Lilly is the largest UK pharmaceutical drug seller, with about 5.1% of 2025 value, USD 1.94 billion, Douglas Insights estimates, ahead of AstraZeneca at 4.6% and Novartis at 3.9%. The top three hold about 13.6% and the top eight 29.7%.

All shares are Douglas Insights estimates, because companies do not report UK sales separately. Lilly leads because tirzepatide alone took about 4.9% of English community cost, per the NHSBSA narrative, and its private weight-loss sales sit on top. AstraZeneca’s total revenue rose 7% at constant exchange rates to USD 46.9 billion in the first nine months of 2026, its results release of 30 October 2026 shows, and we place about USD 1.75 billion of that in the UK. GSK’s third-quarter turnover rose 5% at constant exchange rates to GBP 8.89 billion and its Europe sales 3% to GBP 1.93 billion, per its 28 October 2026 results; we place about USD 1.22 billion with GSK in the UK. Teva, Sandoz, Viatris, Accord and Bristol Myers Squibb share the remaining 70.3% with hundreds of generic suppliers, so the UK field is more fragmented than the U.S. one.

How much does a pharmaceutical drug daily dose cost, and how fast does that price rise?

A daily dose cost an average USD 0.798 in the UK pharmaceutical drug market in 2025, Douglas Insights estimates, 3.4% above the European average of USD 0.772, and the average rises 3.87% a year to about USD 1.17 by 2035.

The English community data give the best visible price signal. The average cost per item rose to GBP 8.97 in 2025/26 from GBP 8.84 in 2024/25, a 1.5% rise, as GBP 11.6 billion was spread across 1.30 billion items, by our calculation from the NHSBSA release. That modest rise hides a wide spread: a generic statin item costs well under GBP 2, while tirzepatide averaged GBP 187 an item. Branded biologics cost USD 15 to USD 40 a daily dose and generics USD 0.08 to USD 0.20, Douglas Insights estimates.

Three forces set the price leg. Mix shift to biologics, GLP-1 drugs and cancer medicines adds about 2.8 points a year; the lower VPAG rate and higher NICE threshold add about 0.85 points; and generic price deflation, which follows each patent expiry, takes back about 0.45 points, all Douglas Insights estimates. List prices in the private market can move far faster than NHS net prices, as the September 2025 Mounjaro increase from GBP 122 to GBP 330 a month showed.

Which rules shape pharmaceutical drug prices, from VPAG to the NICE threshold?

Four rule sets shape UK pharmaceutical drug prices: the VPAG rebate of 14.5% for 2026, capped at 15%; the NICE threshold of GBP 25,000 to GBP 35,000 per QALY from April 2026; the aligned MHRA and NICE pathway from 1 April 2026; and the UK-U.S. pharmaceutical deal of December 2025.

The UK-U.S. deal set the frame. Britain agreed to raise the net price the NHS pays for novel treatments by 25%, to cap the newer-medicines rebate at 15% until the current scheme ends in 2028, and to double spending on new medicines from 0.3% to 0.6% of gross domestic product over ten years, in return for a 0% U.S. tariff on UK medicines for at least three years, Fierce Pharma reported. The ABPI noted that the 15% cap “has not been applied in 2026” because the 14.5% rate came in below it, in its 10 December 2025 statement.

Approval rules set the speed. The MHRA and NICE now run licensing and value decisions “at the same time”, with 27 companies signed up as early adopters, the 17 March 2026 announcement states. Scotland and Wales run their own appraisal bodies, so one UK price can still mean four different access dates.

What if NHS budgets tighten or the pricing reset works: how large is the pharmaceutical drug market in 2035?

The UK pharmaceutical drug market ends 2035 between USD 52.8 billion and USD 67.3 billion across three cases, around a USD 59.8 billion base. NHS budget pressure and the pace of new launches set most of the spread.

In the slower case the VPAG rate rises back toward its 15% cap, NICE approves fewer drugs than the “three to five” extra a year promised, and obesity prescribing stays rationed by NHS England’s phased roll-out. In the faster case Britain meets its 0.6% of GDP target early, biologics launch faster through the aligned pathway and private weight-loss sales keep rising. One extra point of yearly revenue growth adds about USD 5.97 billion to 2035 value, and one point less removes about USD 5.47 billion, Douglas Insights estimates.

Company signals sit near the base case. AstraZeneca’s European revenue grew 10% and GSK’s Specialty Medicines 15% at constant exchange rates in their latest results, while English community cost grew 4%. Our 4.60% sits above the 4.43% Europe rate because Britain is easing rebates while Germany and France tighten.

Douglas Exclusive: the UK Rebate and Threshold Ledger

The UK Rebate and Threshold Ledger is a Douglas Insights model, an estimate rather than an official register, built from 10 inputs: 6 government or NHS documents and 4 company or industry releases. It measures what the pricing reset is worth to UK pharmaceutical drug sales.

The finding, a Douglas Insights estimate: on about USD 22.9 billion of newer-medicine sales, the fall in the total rebate from 22.9% to 15.5% leaves manufacturers about USD 1.69 billion a year more, 4.4% of 2025 UK pharmaceutical drug value. Add three to five extra NICE approvals a year at about USD 60 million each by year three, and the reset is worth about USD 2.65 billion a year by 2030, 5.6% of a USD 47.7 billion 2030 market.

The ledger explains why the UK grows faster than Europe. Germany’s and France’s new rebates take money from manufacturers while Britain hands it back, so launches that were once delayed in Britain now come earlier. The risk is that VPAG rates rise toward the 15% cap if NHS growth slows; at 15% plus the 1% contribution, the relief would shrink by about USD 0.11 billion a year.

How does the methodology turn 47.8 billion daily doses into USD 38.1 billion?

Our methodology multiplies 47.8 billion defined daily doses used in the UK in 2025 by an average USD 0.798 a dose to reach USD 38.1 billion of UK pharmaceutical drug sales, then grows doses 0.70% and price per dose 3.87% a year.

The model covers 5 product types, 8 therapy areas, 3 channels and 4 nations, using 86 data points, 24 sourced and 62 modelled. Doses come from NHS prescribing data per person, grossed up for hospitals, OTC and private supply; price per dose comes from product-type price bands, all Douglas Insights estimates. Arithmetic: 47.8 billion x USD 0.798 = USD 38.1 billion; USD 38.1 billion x (1.0070 x 1.0387)^10 = USD 59.8 billion. Doses reach about 48.1 billion in 2026 and 51.3 billion in 2035; price per dose reaches USD 0.828 in 2026. GBP converts at USD 1.315.

Two cross-checks agree. First, USD 38.1 billion is the United Kingdom row of our Europe model, 9.5% of its USD 401.3 billion total, at the same 4.60% rate. Second, England’s GBP 21.6 billion of NHS medicines spend for 2024/25, grossed up to the UK by population share, gives about GBP 25.6 billion; adding OTC and private sales of about GBP 3.4 billion, a Douglas Insights estimate, gives GBP 29.0 billion, our 2025 figure. AI tools help draft the text and automated checks test the arithmetic, units and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. NHS Business Services Authority Prescription Cost Analysis, England, 2025/26 (2026)
2. NHS Business Services Authority PCA 2025/26 summary narrative (2026)
3. NHS Business Services Authority Prescribing Costs in Hospitals and the Community, England 2024/25 (2025)
4. Department of Health and Social Care VPAG payment percentage for 2026 (2025)
5. ABPI VPAG payment rate for newer medicines will be 14.5% in 2026 (2025)
6. The Pharmaceutical Journal NICE cost-effectiveness thresholds increased (2025)
7. MHRA MHRA 2025-26 annual report and accounts (2026)
8. GOV.UK Joint MHRA-NICE approval process (2026)
9. AstraZeneca AstraZeneca 9M and Q3 2026 results (2026)
10. GSK GSK Q3 2026 results (2026)
11. RTE / Reuters Lilly to hike UK price of Mounjaro (2025)

What counts in the UK pharmaceutical drug study, and what is excluded?

The UK pharmaceutical drug study counts finished prescription and OTC medicines sold in England, Scotland, Wales and Northern Ireland in 2025 at manufacturer invoice prices, before confidential rebates. Pharmacy margins, VAT, active ingredients, exports and veterinary medicines are excluded.

The study splits value by 5 product types, branded small molecules, branded biologics, generics, OTC medicines and biosimilars; by 3 channels, retail pharmacy, hospital pharmacy and online pharmacy; and by 4 nations, England, Scotland, Wales and Northern Ireland. Medicines made in the UK for export count in the buying country’s report. The same build for the United States is in our U.S. Pharmaceutical Drug Market report, and the full European split in our Europe Pharmaceutical Drug Market report.